Anticoagulant fusion proteins and uses thereof
AssigneeBioxodes
InventorsStéphanie DEMOULIN, Edmond GODFROID, Michel GUYAUX, Joël TASSIGNON
Life of this patent
Estimating the term…
Abstract
Disclosed is a fusion protein including an Ixodes ricinus salivary gland polypeptide. In particular, it relates to a fusion protein including at least one Ixodes ricinus salivary gland polypeptide, at least one serum albumin polypeptide and at least one linker peptide. Also disclosed is the use of such a fusion protein for preventing or treating thrombus formation and/or thrombus growth, as well as pharmaceutical compositions, medicaments and methods including such a fusion protein.
Claims15
A fusion protein comprising (i) at least one Ixodes ricinus salivary gland (IrCPI) polypeptide, having an amino acid sequence at least 85% identical to SEQ ID NO:
- 2, (ii) at least one human serum albumin polypeptide and (iii) at least one peptide linker, wherein the fusion protein has an increased circulatory half-life compared to an unfused IrCPI polypeptide, wherein said at least one peptide linker is selected from the group consisting of Gly-rich linkers, Ser-rich linkers, Gly-rich and Ser-rich linkers, Pro-rich linkers, helical linkers, linkers non-cleavable by a protease, linkers cleavable by a protease and a combination thereof.
A pharmaceutical composition or a medicament comprising a fusion protein comprising (i) at least one Ixodes ricinus salivary gland (IrCPI) polypeptide, having an amino sequence at least 85% identical to SEQ ID NO:
- 2, (ii) at least one human serum albumin polypeptide and (iii) at least one peptide linker, wherein the fusion protein has an increased circulatory half-life compared to an unfused IrCPI polypeptide, and at least one pharmaceutically acceptable excipient, and wherein said at least one peptide linker is selected from the group consisting of Gly-rich linkers, Ser-rich linkers, Gly-rich and Ser-rich linkers, Pro-rich linkers, helical linkers, linkers non-cleavable by a protease, linkers cleavable by a protease and a combination thereof.
A method for treating or preventing thrombus formation and/or growth, or thromboinflammation in a subject in need thereof, said method comprising administering to said subject an effective therapeutic dose of a fusion protein comprising (i) at least one Ixodes ricinus salivary gland (IrCPI) polypeptide, having an amino sequence at least 85% identical to SEQ ID NO:
- 2, (ii) at least one human serum albumin polypeptide and (iii) at least one peptide linker, wherein the fusion protein has an increased circulatory half-life compared to an unfused IrCPI polypeptide, wherein said at least one peptide linker is selected from the group consisting of Gly-rich linkers, Ser-rich linkers, Gly-rich and Ser-rich linkers, Pro-rich linkers, helical linkers, linkers non-cleavable by a protease, linkers cleavable by a protease and a combination thereof.
Dependencies are inferred from the claim text.